The Nucleophosmin pipeline drugs market research report outlays comprehensive information on the Nucleophosmin targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Nucleophosmin pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Genito Urinary System which include the indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), and Acute Renal Failure (ARF) (Acute Kidney Injury). It also reviews key players involved in Nucleophosmin targeted therapeutics development with respective active and dormant or discontinued products.
The Nucleophosmin pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, IND/ CTA Filed, and Preclinical stages are 1, 1, and 4 respectively.
Nucleophosmin overview
Nucleophosmin is intricately involved in a myriad of cellular processes, including but not limited to ribosome biogenesis, centrosome duplication, protein chaperoning, histone assembly, cell proliferation, and the regulation of tumor suppressors p53/TP53 and ARF. It binds to ribosomes, presumably facilitating their nuclear export, and associates with nucleolar ribonucleoprotein structures while binding to single-stranded nucleic acids. Acting as a chaperonin for core histones H3, H2B, and H4, it stimulates the endonuclease activity of APEX1 on apurinic/apyrimidinic (AP) double-stranded DNA while inhibiting the same activity on AP single-stranded RNA. Nucleophosmin may exert control over APEX1 endonuclease activity within nucleoli dedicated to repairing AP on rDNA and removing oxidized rRNA molecules. In collaboration with BRCA2, Nucleophosmin regulates centrosome duplication and, in turn, centriole duplication. Notably, its phosphorylation by PLK2 can trigger centriole replication. Additionally, Nucleophosmin plays a role in negatively regulating the activation of EIF2AK2/PKR, thereby suppressing apoptosis through the inhibition of EIF2AK2/PKR autophosphorylation. Furthermore, it acts as an antagonist to the inhibitory effect of ATF5 on cell proliferation and alleviates ATF5-induced G2/M blockade. The multifaceted involvement of Nucleophosmin underscores its significance in orchestrating diverse cellular functions and maintaining cellular homeostasis.
For a complete picture of Nucleophosmin’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
